



phi

PHASE
HOLOGRAPHIC
IMAGING

Phase Holographic: Annual Report 2024/25

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811 and headquartered in Lund, hereby present the annual report for the financial year May 1, 2024 – April 30, 2025.

The annual report is available on the company's website: <http://phiab.com/annual-report/2024-25/>

This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-09-2025 11:03 CET.

For additional information, please contact:

Patrik Eschricht, CEO

E-mail: ir@phiab.com

Web: www.phiab.com – [Live cell imaging & analysis](#)

About PHI

Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.